Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStopping Wegovy raises a real concern: will the weight come back? Evidence from clinical trials suggests most people do regain a significant portion of lost weight after discontinuing semaglutide, but the degree and speed vary considerably depending on what habits are in place when treatment ends. Coming off Wegovy without gaining weight is not guaranteed, yet it is far more achievable with a structured plan than without one. This page explains what the research shows, what you can do at each stage, and how a prescriber should guide the process. Wegovy is a prescription-only medicine; any decision about stopping or tapering must involve the clinician overseeing your care.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The starting point is a conversation, not a sudden stop. Before your last pen arrives, a prescriber should understand your reason for discontinuing — whether that is cost, side effects, reaching your goal, pregnancy planning, or something else entirely. Each reason shapes the plan differently. If you are stopping because you have reached a stable weight and feel ready, the transition looks very different from stopping due to an adverse reaction.
At this stage, your prescriber may discuss whether stepping down through lower doses over several weeks is appropriate rather than stopping at the maintenance dose. There is no universal protocol written into the semaglutide licence for tapering, but clinical experience suggests the adjustment period is easier when appetite does not change overnight. Stopping Wegovy safely involves this kind of staged thinking, it is worth reading if you are at the early planning stage.
One thing the prescriber will also do is document your current weight, review any conditions that originally qualified you for treatment, and set a realistic expectation. Semaglutide takes time to reach its full effect, and it also takes time to clear the system, roughly five weeks for the drug to fall below meaningful plasma levels after the last dose.
The six to eight weeks before your final dose are arguably the most important. Semaglutide's appetite suppression means many people eat less without noticing, and some of that reduction falls on protein. Muscle mass is the main driver of resting metabolic rate, and losing it during treatment makes weight regain more likely afterwards.
Practical targets to establish before stopping: a daily protein intake that supports your lean body mass (your prescriber or a dietitian can give a figure specific to you), at least two sessions of resistance-based activity per week, and consistent meal timing that does not rely on the medicine to regulate hunger. The research on not regaining weight after Wegovy consistently points to these same foundations.
This is also the moment to review sleep and stress, both of which directly affect the hormones that drive appetite. Cortisol and ghrelin (hunger-promoting hormones) rise with poor sleep and chronic stress. GLP-1 medicines dampened some of that signalling; once they are gone, the physiological pressure returns. Building routines that manage these factors now, while appetite is still lower, is genuinely easier than doing it afterwards.
The STEP 1 extension data, published in the New England Journal of Medicine, showed that participants who stopped semaglutide 2.4mg regained about two-thirds of their lost weight within a year, and most of that regain happened in the first twelve weeks. That window is where active effort has the highest return.
What works in this period: structured eating with set meal times rather than relying on hunger cues (which will feel louder than they did on treatment), protein at every meal, deliberate monitoring of portions without obsessive restriction, and walking or other low-intensity daily movement alongside the two resistance sessions per week. Our guidance on whether and how you can come off semaglutide covers these strategies in more detail across different clinical situations.
It is also worth noting that some people return to GLP-1 treatment after a planned break. Obesity is a chronic condition with a strong biological component, not a willpower problem with a fixed endpoint. If weight begins to return substantially despite consistent effort, discussing resuming treatment is a legitimate option, not a failure. The Wegovy overview at nume covers what restarting looks like from a clinical standpoint.
The NHS's weight-management guidance and the evidence base both point to the same conclusion: the habits that prevent regain are the same ones that would have produced modest weight loss on their own, just now more manageable because treatment has already lowered the set-point. NHS England's guidance on weight-management injections explicitly frames these medicines as a platform to build lasting behaviour change, not a standalone fix.
Practically, a sustainable post-Wegovy routine looks like: a weekly weigh-in or clothes-fit check to catch early regain before it compounds, a protein-forward eating pattern that does not require meticulous tracking indefinitely, a form of movement that is genuinely enjoyable rather than punitive, and an honest relationship with hunger, recognising it as a signal to respond to, not suppress or ignore. If you are still weighing up the decision to stop, reading about how to come off Wegovy can help you think through what the process involves before you commit to a plan.
If you want an objective assessment of where you stand and what options remain, our clinical team at nume reviews each patient's situation individually. You can speak to our prescribers to discuss your personal circumstances, whether you are mid-treatment, planning to stop, or wondering about the next step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.